BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 247 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,099,000 | +3.8% | 7,268 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $1,059,000 | +22.9% | 7,268 | 0.0% | 0.01% | +50.0% |
| Q1 2022 | $862,000 | -14.0% | 7,268 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,002,000 | -0.8% | 7,268 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $1,010,000 | +43.1% | 7,268 | 0.0% | 0.00% | +33.3% |
| Q2 2021 | $706,000 | +42.1% | 7,268 | 0.0% | 0.00% | +50.0% |
| Q1 2021 | $497,000 | -20.2% | 7,268 | 0.0% | 0.00% | -33.3% |
| Q4 2020 | $623,000 | +32.0% | 7,268 | 0.0% | 0.00% | +50.0% |
| Q3 2020 | $472,000 | -11.1% | 7,268 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $531,000 | +115.0% | 7,268 | 0.0% | 0.00% | +50.0% |
| Q1 2020 | $247,000 | -32.0% | 7,268 | +8.9% | 0.00% | 0.0% |
| Q4 2019 | $363,000 | +30.1% | 6,676 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $279,000 | -4.5% | 6,676 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $292,000 | – | 6,676 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 896,844 | $123,594,000 | 67.92% |
| RP Management, LLC | 1,111,111 | $153,122,000 | 64.09% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,075,402 | $286,011,000 | 40.64% |
| ARS Investment Partners, LLC | 463,392 | $63,860,000 | 5.86% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 300,373 | $41,394,000 | 4.76% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 80,348 | $11,073,000 | 4.49% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 139,900 | $19,282,000 | 4.30% |
| Avidity Partners Management LP | 1,140,000 | $157,103,000 | 3.33% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 200,000 | $27,562,000 | 3.17% |
| Eventide Asset Management | 1,635,000 | $225,319,000 | 2.88% |